Summary

for people ages 2-7 (full criteria)
healthy people welcome
at Oakland, California and other locations
study started
estimated completion

Description

Summary

The Dissemination and Implementation of Stroke Prevention Looking at the Care Environment (DISPLACE) study is a multi-center, national, National Heart, Lung and Blood Institute (NHLBI)-funded grant to look at the real-world implementation of stroke prevention guidelines (STOP Protocol) in which transcranial Doppler (TCD), a measure of cerebral blood vessel velocity, is used to screen for stroke risk in children ages 2-16 with sickle cell anemia (SCA). Part 3 of the DISPLACE study is an implementation clinical trial designed to test novel implementation strategies with the goal of improving adherence and implementation of stroke screening. 16 of the lowest scoring implementation rates from DISPLACE Part 1 will participate in DISPLACE Part 3. All original 28 sites from DISPLACE Parts 1 and 2 will receive a patient and provider educational intervention including a re-branding of the TCD as "Sickle Stroke Screen" with a new infographic and educational materials. The 16 sites with moving to Part 3 will be provided a Provider reminder strategy, which is a web based application designed to remind providers of when patients are due for their Sickle Stroke Screen. These 16 sites will be randomized and 8 will be given an additional Patient Communication Strategy. These sites will have a single designed coordinator with whom patients will communicate with about scheduling, rescheduling, and any other questions regarding their Sickle Stroke Screen. Upon completion, data will be analyzed to compare those who have had TCD screenings done appropriately and those who did not as well as the overall effect of the multi level interventions on the changes in TCD rates.

Official Title

Dissemination and Implementation of Stroke Prevention Looking at the Care Environment (DISPLACE) Part 3

Keywords

Sickle Cell Disease Anemia, Sickle Cell Provider-level intervention Patient-level intervention

Eligibility

You can join if…

Open to people ages 2-7

  • Patients with sickle cell anemia (SCA) identified at each institution through International Classification of Diseases 9/10 (ICD-9/ICD-10) codes and local patient databases.
  • Patients must have been seen by the designated institution (documented in medical record) a minimum of two times in the either inpatient or outpatient setting at the institution between the years of 01/01/2018-12/31/2019.
  • Patients identified will include those currently aged 2-7. Thus children born from 2012 and onward.
  • Patients already receiving primary or secondary stroke prevention therapy with CRCT will be included in registration in Web Data Coordination Unit (WEBDCU) but not included in PROVIDER MINDER as they do not require ongoing TCD/SICKLE STROKE SCREEN based on protocol.

You CAN'T join if...

  • Patients who do not have SCA
  • Patients who were born before 2012 and therefore do not meet age criteria.

Locations

  • UCSF Benioff Children's Hospital Oakland not yet accepting patients
    Oakland California 94609 United States
  • Arkansas Children's Research Institute not yet accepting patients
    Little Rock Arkansas 72202 United States

Details

Status
not yet accepting patients
Start Date
Completion Date
(estimated)
Sponsor
University of Alabama at Birmingham
ID
NCT04173026
Study Type
Interventional
Last Updated